Deciphering copy number variations and gene implications in an Egyptian cohort with autism spectrum disorders.

Researchers studied the DNA of 40 Egyptian children with autism to look for genetic changes that might explain their condition. They found significant genetic differences in about 1 in 6 children, affecting specific areas of chromosomes linked to autism. Children with these genetic changes had more severe repetitive behaviors, more trouble with changes in routine, and stronger reactions to tastes, smells, and touch. Some also had unusually small or large heads or seizures.

These genetic changes were new and not inherited from parents.

This study examined genetic variations called copy number variations (CNVs) in 40 Egyptian children with autism spectrum disorder using advanced genetic testing methods. Researchers found clinically significant CNVs in 17.5% of patients, affecting specific chromosomal regions (16p11.2, 15q11q13, 22q11.2, and 7q11.23) previously linked to autism. Children with these CNVs showed more severe symptoms in specific areas: repetitive behaviors, difficulty adapting to changes, and sensory responses. Some also had physical features like microcephaly, macrocephaly, or epilepsy.

The genetic variations were confirmed to be new (de novo) rather than inherited from parents. The affected genes primarily relate to brain function, supporting the neurological basis of autism.

Chromosomal microarray testing appears valuable for autism diagnosis, particularly in identifying specific genetic subtypes. Genetic findings may help predict certain behavioral patterns and inform personalized treatment approaches. Results support the importance of genetic counseling for families, especially regarding recurrence risks when CNVs are de novo.

Small sample size of 40 patients limits generalizability. Study focused on Egyptian population which may not represent other ethnicities. Limited follow-up on functional impact of identified genetic variations. No comparison with neurotypical controls mentioned.

Genetic factors are major contributors to autism spectrum disorders (ASD), with copy number variations (CNVs) playing a significant role. Our objective was to identify and assess CNVs and their associated gene-level impacts in Egyptian ASD patients. Our cohort comprised 40 non-syndromic ASD children, ranging in age from one year and nine months to 12 years. We conducted karyotyping, multiple ligation-dependent probe amplification (MLPA), Methylation-Specific MLPA (MS-MLPA), and chromosomal microarray (CMA) analyses for all patients.

Additionally, quantitative real-time PCR (qPCR) analyses were performed on selected patients and their parents. We identified pathogenic or likely pathogenic CNVs in seven patients (17.5%), variants of uncertain significance (VUS) in 10 patients (25%), and classified other variants as benign. Pathogenic or likely pathogenic CNVs affected chromosomes 16p11.2 (two patients), 15q11q13 (three patients), 22q11.2 (one patient), and 7q11.23 (one patient). Many of the affected genes are associated with neuronal functions.

Patients with CNVs exhibited increases in three parameters on the Children's Autism Rating Scale (CARS): restrictive and repetitive behavior, adaptation to changes, and responses to taste, smell, and touch. According to the Autism Diagnostic Interview-Revised (ADI-R), patients with pathogenic or likely pathogenic CNVs had an increased third parameter for restricted, repetitive, and stereotyped patterns of behavior. Patients with pathogenic or likely pathogenic CNVs demonstrated some clinical manifestations involving microcephaly (two patients), macrocephaly (one patient), and abnormal electroencephalogram (EEG) with generalized epileptic focus (two patients). qRT-PCR was performed for some parents, and the CNVs were found to be de novo. CNV detection via CMA proved invaluable and is considered a primary tool in ASD diagnosis.

Distinguishing between inherited and de novo CNVs is crucial for accurate genetic counseling. Most genes involved in the detection of pathological or likely pathogenic CNVs are linked to neuronal functions, and these CNVs impact specific parameters in CARS and ADI-R assessments. Future efforts should prioritize a more comprehensive understanding of the genetic underpinnings of ASD, enabling the adoption of personalized treatment strategies.